Discover the latest insights on geographic atrophy, its causes, symptoms, and innovative treatment options to manage this eye condition effectively. In this segment, the expert faculty examine a ...

Panelists discuss how aflibercept’s structural design and the higher molar dose of its 8-mg formulation enhance VEGF binding, treatment durability, and clinical predictability. The panel reviews why ...

Ashkan Abbey, MD, FASRS, FAAO, from Texas Retina Associates discussed EYP-1901, an innovative intravitreal insert that releases vorolanib, a potent tyrosine kinase inhibitor designed to treat retinal ...

The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life. Frank Holz, MD, FEBO, FARVO, a retina specialist from Bonn, Germany, discusses ...

Catch up on this week's highlights in retina. Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa. Beacon Therapeutics recently revealed topline data ...

Neurotech Pharmaceuticals performs the first ENCELTO procedure. Neurotech Pharmaceuticals recently announced the first commercial manufacturing, shipment, and surgical procedure of the first and only ...

Dilsher S. Dhoot, MD, FASRS, shares insights on avoralstat, a promising treatment for diabetic macular edema, at ASRS 2025. The American Society of Retina Specialists (ASRS) is holding their 2025 ...

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD. EyePoint Pharmaceuticals recently announced the completion of ...

Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043. Kiora Pharmaceuticals recently announced the receipt of ...

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation. Today Nanoscope Therapeutics announced its ...

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience. Affecting more than 21 million people globally, DME ...